Posted in Sponsored Feature,Supplements
07th May 2019
This article was initiated, developed and funded by Merck
Posted in Courses & Conferences,Online First,Sponsored Feature
14th Dec 2018
Download our 8 page newsletter, produced in association with LivaNova
Posted in Online First,Sponsored Feature
07th Dec 2017
Sponsored feature: Highlights from the National Epilepsy Nurse Meeting
Posted in Online First,Special Feature,Sponsored Feature
10th Jul 2017
Developed and funded by Sanofi Genzyme
Posted in Australia/New Zealand,Online First,Special Feature,Sponsored Feature
01st Feb 2017
STADA Australia continues to innovate in Parkinson’s Disease with MOVAPO® pre-filled syringes (PFS) Parkinson’s Disease is a surprisingly prevalent condition with an estimated 10 million people worldwide and roughly 70,000 Australians (1 in every 340 people) suffering from the condition.1 It is the second most prevalent neurological condition exceeded only by dementia. It is more common […]
Posted in Book Reviews,Industry News,Sponsored Feature
08th Dec 2016
Book News
Posted in Courses & Conferences,Sponsored Feature,Supplements
11th Nov 2015
News from the recent ILAE meeting
Posted in Courses & Conferences,Sponsored Feature
02nd Jun 2015
Report from Britannia Pharmaceuticals on their plenary session on PD treatment, held at the 9th CONy Congress in Budapest, Hungary, March 2015
Posted in Sponsored Feature,Supplements
15th Apr 2015
Summary Perampanel has a novel mode of action based on a rational hypothesis of seizure initiation and spread. This can be considered when discussing the possibility of initiating perampanel treatment in patients with partial onset seizures who have failed to gain control with other AEDs. Perampanel is an easy to use antiepileptic treatment that, based […]
Posted in Sponsored Feature
15th Apr 2015
ACNR 2015;15(1);28-29. Online 15/04/15
